MedTrace Logo

MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.

NCT02712203 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5808

Last updated 2016-03-18

No results posted yet for this study

Summary

Healthy children who received two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella vaccine (MMR) or measles-mumps-rubella-varicella vaccine (MMRV) in their second year of life.The purpose of this study is to assess the effect of the age at administration of the first dose on the reactogenicity and immunogenicity of the measles component of these vaccines.

In addition, this study will evaluate if the effect of the age at first dose is modified by the type of vaccine administered.

Conditions

Interventions

BIOLOGICAL

MMR vaccine / MMRV vaccine

Subcutaneous injection, two doses

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • CHU de Quebec-Universite Laval

    lead OTHER

Principal Investigators

  • Gaston De Serres, MD, PhD · CHU de Quebec-Universite Laval

Eligibility

Min Age
11 Months
Max Age
22 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-07-31
Primary Completion
2010-07-31
Completion
2016-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02712203 on ClinicalTrials.gov